Massachusetts Financial Services Co. MA grew its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 8.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,159 shares of the company’s stock after purchasing an additional 10,941 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Sanofi were worth $6,849,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Envestnet Asset Management Inc. lifted its position in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Sanofi by 11.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 135,751 shares of the company’s stock valued at $6,587,000 after buying an additional 14,455 shares during the period. Wrapmanager Inc. boosted its stake in Sanofi by 18.1% during the second quarter. Wrapmanager Inc. now owns 8,543 shares of the company’s stock valued at $415,000 after buying an additional 1,310 shares in the last quarter. Parallel Advisors LLC grew its holdings in Sanofi by 14.6% during the second quarter. Parallel Advisors LLC now owns 7,732 shares of the company’s stock worth $375,000 after acquiring an additional 987 shares during the period. Finally, HBK Sorce Advisory LLC bought a new stake in Sanofi in the second quarter worth about $208,000. 10.04% of the stock is currently owned by institutional investors.
Sanofi Stock Performance
Sanofi stock opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $145.96 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm’s 50 day simple moving average is $54.34 and its 200-day simple moving average is $50.48.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.
Get Our Latest Stock Report on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
- Five stocks we like better than Sanofi
- How to Choose Top Rated Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 9/16 – 9/20
- The How and Why of Investing in Gold Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.